

Press Release

Verovaccines Positions for Growth: Management Transition to Accelerate Value Creation

Halle (Saale), Germany – February 16, 2026 – Verovaccines GmbH, a biotechnology company advancing a highly scalable vaccine technology platform for the animal health sector, today announced a strategic change in its executive leadership. Prof. Dr. Sven-Erik Behrens, Managing Director and co-founder, will transition to the Board of Directors, and Dr. Ulrike Diesterbeck, DVM, previously Head of Vaccine Development, will assume the role of Managing Director effective immediately.

Verovaccines has built an innovative, standardized vaccine development and production platform designed to enable rapid, low-cost, and antigen-agnostic vaccine creation. The single-line manufacturing concept allows all vaccines to be produced within the same process infrastructure, resulting in exceptionally low cost of goods and significant scalability advantages. This capability uniquely positions Verovaccines to address global vaccine demand with improved capital efficiency and speed—attributes directly aligned with the evolving priorities of the animal health and biopharmaceutical markets.

The company is approaching a key regulatory inflection point, with its first vaccine candidate under review by the European Medicines Agency (EMA). This anticipated approval will represent the platform's proof of concept and open the path for pipeline expansion as a full developer across multiple species and disease indications.

Dr. Hanjo Hennemann, Managing Director and co-founder of Verovaccines, commented: "I am truly grateful to Prof. Behrens for his exceptional commitment and contributions as a scientist, virologist, inventor, and co-founder. His work has laid the foundation for Verovaccines' growth and achievements to date. I look forward to continuing our collaboration with him at the Board level."

Dr. Ulrike Diesterbeck, DVM, newly appointed Managing Director, added: "Contributing to the forthcoming approval of our first vaccine has been tremendously rewarding. I am excited to lead the next phase of product development and pipeline expansion, focusing on highly differentiated vaccine candidates designed to capture significant, clearly identified market opportunities."

With the leadership transition, Verovaccines is now positioned to pursue strategic partnerships, licensing projects, and investment opportunities that leverage its technology's transformative potential and operational efficiency.

About Verovaccines GmbH

Verovaccines GmbH is a platform-focused biopharmaceutical company headquartered in Halle (Saale), Germany. Its proprietary vaccine technology enables rapid and standardized development and production, providing scalable manufacturing across diverse pathogens and animal species. By combining platform efficiency with strong scientific innovation, Verovaccines aims to redefine the economics and speed of vaccine development and supply in animal health markets worldwide.

Contact

Verovaccines GmbH
Bluecherstr. 26
06120 Halle (Saale)
Germany

Email: info@verovaccines.com

Website: <https://verovaccines.com/>